Presentation Information
[Pe-041-2]Safety of risdiplam in patients with spinal muscular atrophy: a postmarketing surveillance study
Masahisa Katsuno1, Kayoko Saito2, Toshio Saito3, Reiko Arakawa4, Yasuhiro Takeshima5, Hisahide Nishio6, Yuka Ishikawa7, Takahiko Tsumuraya8, Hiromitsu Kawata9, Yuki Miyano8, Hirofumi Komaki10 (1.Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2.Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan, Japan, 3.Division of Child Neurology, Department of Neurology, Osaka Toneyama Medical Center, Osaka, Japan, Japan, 4.Department of Genomic Medicine, National Center for Global Health and Medicine, Tokyo, Japan, Japan, 5.Department of Pediatrics, Hyogo Medical University Hospital, Hyogo, Japan, Japan, 6.Faculty of Rehabilitation, Kobe Gakuin University, Hyogo, Japan, Japan, 7.Center for Neuromuscular Disease, Child Health and Development, National Hospital Organization, Hokkaido Medical Center, Sapporo, Hokkaido, Japan, Japan, 8.Drug Safety Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, Japan, 9.Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, Japan, 10.Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan, Japan)
1995年名古屋大学医学部を卒業し、名古屋第二赤十字病院にて臨床研修。2003年名古屋大学大学院医学系研究科を修了した後、同客員研究員・高等研究院特任講師などを経て2015年7月から現職。卓越大学院CIBoGプログラムコーディネーター。日本学術会議連携会員。